

ABSTRACT

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and/or multiple myeloma (MM) as possible side effects; wherein the patients and/or prescribing physicians and other medical care providers are advised to monitor for such conditions and employ methods that will improve the therapeutic outcome in the few patients who experience MGUS, SMM, and/or MM associated with zonisamide therapy.